Do you want to read an article? Please log in or register.
Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context
Further Publications
Related content
Macular Diseases
Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry
Ophthalmology.
Bhandari S, Nguyen V, Arnold J, Young S, Banerjee G, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.10.006.
Macular Diseases
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
BMC Ophthalmol.
Waizel M, Todorova MG, Masyk M, Wolf K, Rickmann A, Helaiwa K, Blanke BR, Szurman P
doi: 10.1186/s12886-017-0471-x.
COMMENTED
Macular Diseases
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)
doi: 10.1016/j.ophtha.2020.03.021.
Macular Diseases
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
Adv Ther.
Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J
doi: 10.1007/s12325-019-01147-6.
Macular Diseases
Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab
Clin Exp Ophthalmol.
Spooner K, Fraser-Bell S, Hong T, Chang A
doi: 10.1111/ceo.13636.
Macular Diseases
The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration
BMC Ophthalmol.
Kovacs A, Kiss T, Rarosi F, Somfai GM, Facsko A, Degi R
doi: 10.1186/s12886-018-0960-6.
RECOMMENDED
Macular Diseases
Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
Ophthalmology.
Bhandari S, Nguyen V, Fraser-Bell S, Mehta H, Viola F, Baudin F, Gabrielle PH, Creuzot-Garcher C, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.11.018.
Macular Diseases
Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry
Br J Ophthalmol
Hunt AR, Nguyen V, Creuzot-Garcher CP, Alforja S, Gabrielle PH, Zarranz-Ventura J, Guillemin M, Fraser-Bell S, Casaroli Marano RP, Arnold J, McAllister IL, O'Toole L, Gillies MC, Barthelmes D, Mehta H
doi: 10.1136/bjophthalmol-2020-318491
ConjunctivitisFlammer SyndromeMacular DiseasesRetinal DiseasesCataracts
12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
Acta Ophthalmol
Niedzwiecki M, Hunt A, Nguyen V, Mehta H, Creuzot-Garcher C, Gabrielle PH, Guillemin M, Fraser-Bell S, Arnold J, McAllister IL, Gillies M, Barthelmes D
doi: 10.1111/aos.15014